Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Travels to the tropics: Deutschtum and Fedor Krause's visits to Brazil.
Figueiredo EG, Almeida da Silva S, Jacobsen Teixeira M, Belykh E, Carotenuto A, Moreira LB, Spetzler RF, Dagi TF, Preul MC. Figueiredo EG, et al. Among authors: carotenuto a. J Neurosurg. 2019 Apr 5;132(6):1977-1984. doi: 10.3171/2018.12.JNS182063. J Neurosurg. 2019. PMID: 30952119
Genetic Alterations in Intervertebral Disc Disease.
Martirosyan NL, Patel AA, Carotenuto A, Kalani MY, Belykh E, Walker CT, Preul MC, Theodore N. Martirosyan NL, et al. Among authors: carotenuto a. Front Surg. 2016 Nov 21;3:59. doi: 10.3389/fsurg.2016.00059. eCollection 2016. Front Surg. 2016. PMID: 27917384 Free PMC article. Review.
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
Monteiro I, Nicolella V, Fiorenza M, Novarella F, Carotenuto A, Lanzillo R, Mauriello L, Scalia G, Castaldo G, Terracciano D, Brescia Morra V, Moccia M. Monteiro I, et al. Among authors: carotenuto a. J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434-w. Online ahead of print. J Neurol. 2024. PMID: 38777960
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: carotenuto a. Mult Scler Relat Disord. 2024 Apr 6;87:105594. doi: 10.1016/j.msard.2024.105594. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
326 results